Abstract
The development of technologies to produce recombinant proteins for use as vaccines has made substantial advances during the past decade. In particular, a number of expression systems have been designed to increase the immunogenicity of proteins and peptides by presenting them as polyvalent, paniculate structures. Examples of such carrier systems include both the core and surface proteins of hepatitis B virus and poliovirus which have been used to present a variety of immunogens in a particulate form; these include epitopes derived from foot-and-mouth disease virus (Clarke et al., 1987), human immunodeficiency virus (HIV-1) (Michel et al., 1988), and human papillomavirus (Jenkins et al., 1991). In addition, synthetic systems such as immunostimulating complexes (ISCOMs) (Morein et al., 1987; see Chapter 23) and liposomes (Harding et al., 1991; see Chapter 13) have been used to induce both cellular and humoral responses to a range of proteins. Both of these systems result in multiple copies of the protein being presented to the immune system as part of a relatively large particle.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams, S. E., Mellor, J., Gull, K., Sim, R. B., Tuite, M. F., Kingsman, S. M., and Kingsman, A. J., 1987a, The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins, Cell 49:111–119.
Adams, S. E., Dawson, K. M., Gull, K., Kingsman, S. M., and Kingsman, A. J., 1987b, The expression of hybrid Ty virus-like particles in yeast, Nature 329:68–70.
Adams, S. E., Senior, J. M., Kingsman, S. M., and Kingsman, A. J., 1988, Induction of HIV antibodies by Ty:HIV hybrid virus-like particles, in: Technological Advances in Vaccine Development (L. Lasky, ed.) Liss, New York, pp. 117–126.
Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Worm, F. M., Herschberg, R. D., Cobb, E. K., and Eichberg, J. W., 1990, Protection of chimpanzees from infection with HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp 160, Nature 345:622–625.
Boeke, J. D., Garfinkel, D. J., Styles, C. A., and Fink, G. R., 1985, Ty elements transpose through an RNA intermediate, Cell 40:491–500.
Braddock, M., Chambers, A., Wilson, W., Esnouf, M. P., Adams, S. E., Kingsman, A. J., and Kingsman, S. M., 1989, HIV-1 TAT ‘activates’ presynthesized RNA in the nucleus, Cell 58:269–279.
Burns, N. R., Saibil, H. R., White, N. S., Pardon, J. F., Timmins, P. A., Richardson, S. M. H., Richards, B. M., Adams, S. E., Kingsman, S. M., and Kingsman, A. J., 1990a, Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles, EMBO J. 11:1155–1164.
Burns, N. R., Gilmour, J. E. M., Kingsman, S. M., Kingsman, A. J., and Adams, S. E., 1990b, Production and purification of hybrid Ty-VLPs, Methods Mol. Biol. 8:277–285.
Cheingsong-Popov, R., Panagiotidi, C., Bowcock, S., Aronstam, A., Wadsworth, J., and Weber, J., 1991, Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection, Br. Med. J. 302:23–26.
Clare, J., and Farabaugh, P., 1985, Nucleotide sequence of a yeast Ty element: Evidence for an unusual mechanism of gene expression, Proc. Natl. Acad. Sci. USA 82:2829–2833.
Clarke, B. E., Newton S. E., Carroll, A. R., Francis, M. J., Appleyard, G., Syred, A. D., Highfield, P. E., Rowlands, D. J., and Brown, F., 1987, Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein, Nature 330:381–384.
Deres, K., Schild, H., Weismuller, K. H., Jung, G., and Rammensee, H. G., 1989, In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine, Nature 342:561–564.
Dobson, M. J., Mellor, J., Fulton, A. M., Roberts, N. A., Bowen, B. A., Kingsman, S. M., and Kingsman, A. J., 1984, The identification and high level expression of a protein encoded by the yeast Ty element, EMBO 73: 1115–1119.
Eichinger, D. J., and Boeke, J. D., 1988, The DNA intermediate in yeast Ty1 transposition copurifies with virus-like particles: Cell-free Ty1 transposition, Cell 54:955–966.
Elder, R. T., Loh, E. Y., and Davis, R. W., 1983, RNA from the yeast transposable element Ty1 has both ends in the direct repeats, a structure similar to retrovirus RNA, Proc. Natl. Acad. Sci. USA 80:2432–2436.
Emini, E. A., Scheif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshi, S., Putney, S. D., Matsushita, S., Cobb, K. E., Jett, C. M., Eichberg, J. W., and Murthy, K. K., 1992, Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody, Nature 355:728–729.
Fulton, A. M., Mellor, J., Dobson, M. J., Chester, J., Warmington, J. R., Indge, K. J., Oliver, S. G., de la Paz, P., Wilson, W., Kingsman, A. J., and Kingsman, S. M., 1985, Variants within the yeast Ty sequence family encode a class of structurally conserved proteins, Nucleic Acids Res. 13:4097–4112.
Fulton, A. M., Adams, S. E., Rathjen, P. D., Wilson, W., Kingsman, S. M., and Kingsman, A. J., 1990, The biology and exploitation of the yeast retrotransposon Ty, Adv. Gene Technol. 1:1–20.
Gao, X.-M., Zheng, B., Liew, F. Y., Brett, S., and Tite, J., 1991, Priming of influenza virus-specific cytotoxic T lymphocytes in vivo by short synthetic peptides, J. Immunol. 147:3268–3273.
Gheyson, D., Jacobs, E., DeForesta, F., Thiriart, C., Francotte, M., Thines, D., and de Wilde, M., 1989, Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirusinfected cells, Cell 59:103–112.
Gilmour, J. E. M., Senior, J. M., Burns, N. R., Esnouf, M. P., Gull, K., Kingsman, S. M., Kingsman, A. J., and Adams, S. E., 1989, A novel method for the purification of HIV-1 p24 protein from hybrid Ty-VLPs, AIDS 3:717–723.
Gilmour, J. E. M., Read, S. J., Eglin, R., Ryan, C., Graff, N. R., Stenner, N., Kingsman, S. M., Kingsman, A. J., and Adams, S. E., 1990, Performance characteristics of a novel immunoassay based on hybrid Ty virus-like particles, AIDS 4:967–973.
Griffiths, J. C., Berrie, E. L., Holdsworth, L. N., Moore, J. P., Harris, S. J., Senior, J. M., Kingsman, S. M., Kingsman, A. J., and Adams, S. E., 1991, Induction of high-titer neutralizing antibodies using hybrid human immunodeficiency virus V3-Ty virus-like particles in a clinically relevant adjuvant, J. Virol. 65:450–456.
Griffiths, J. C., Harris, S. J., Layton, G. T., Berrie, E. L., French, T. J., Burns, N. R., Adams, S. E., and Kingsman, A. J., 1993, Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion, J. Virol. 67:3191–3198.
Harding, C. V., Collins, D. S., Kanagawa, O., and Unanue, E. R., 1991, Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation, J. Immunol. 147:2860–2863.
Harris, S. J., Gearing, A. J. H., Layton, G. T., Adams, S. E., Kingsman, S. M., and Kingsman, A. J., 1992, Enhanced proliferative cellular responses to V3 peptide and gp120 following immunization with V3:Ty virus-like particles, Immunology 77:315–321.
Hart, M. K., Weinhold, K. J., Scearce, R. M., Washburn, E. M., Clark, C. A., Palker, T. J., and Haynes, B. F., 1991, Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides, Proc. Nail. Acad. Sci. USA 88:9448–9452.
Jenkins, O., Cason, J., Burke, K. L., Lunney, D., Gillen, A., Patel, D., McCance, D. J., and Almond, J. W., 1991, An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16, J. Virol. 64:1201–1206.
Kast, W. M., Bronkhorst, A. M., de Waal, L. P., and Melief, C. J. M., 1986, Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection: Protection by T cells is MHC-restricted, J. Exp. Med. 164:723–738.
Kast, W. M., Roux, L., Curren, J., Blom, H. J. J., Voordouw, A. C., Meloen, R. H., Kolakofsky, D., and Melief, C. J. M., 1991, Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide, Proc. Nad. Acad. Sci. USA 88:2283–2287.
Kingsman, A. J., Adams, S. E., Burns, N. R., and Kingsman, S. M., 1991, Retroelement particles as purification, presentation and targeting vehicles, Trends Biotechnol. 9:303–309.
Kingsman, S. M., and Kingsman, A. J., 1988, Polyvalent recombinant antigens: A new vaccine strategy, Vaccine 6:304–306.
Kitchen, L. W., Barin, F., Sullivan, J. L., McLane, M. F., Brettler, D. B., Levine, P. H., and Essex, M., 1984, Aetiology of AIDS — antibodies to human T-cell leukaemia virus (type III) in haemophiliacs, Nature 312:367–369.
Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., and Rock, K. L., 1993, Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages, Proc. Natl. Acad. Sci. USA 90:4942–4946.
Lange, J. M. A., Paul, D. A., Huisman, H. G., de Wolf, F., van den Berg, H., Coutinho, R. A., Danner, S. A., van der Noorda, J., and Goudsmit, J., 1986, Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS, Br. Med. J. 293:1459–1463.
Layton, G. T., Harris, S. J., Gearing, A. J. H., Hill-Perkins, M., Cole, J. S., Griffiths, J. C., Burns, N. R., Kingsman, A. J., and Adams, S. E., 1993, Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like-particles, J. Immunol. 151:1097–1107.
Macatonia, S. E., Taylor, P. M., Knight, S. C., and Askonas, B. A., 1989, Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro, J. Exp. Med. 169:1255–1264.
McMichael, A. J., Gotch, F. M., Noble, G. R., and Beare, P. A. S., 1983, Cytotoxic T cell immunity to influenza, N Engl J. Med. 309:13–17.
Martin, S. J., Vyakarnum, A., Cheingsong-Popov, R., Callow, D., Jones, K. L., Senior, J. M., Adams, S. E., Kingsman, A. J., Matear, P., Gotch, F. M., McMichael, A. J., Roitt, I. M., and Weber, J. N., 1993, Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses, AIDS 7:1315–1323.
Mellor, J., Fulton, A. M., Dobson, M. J., Wilson, W., Kingsman, S. M., and Kingsman, A. J., 1985a, A retrovirus-like strategy for expression of a fusion protein encoded by yeast retrotransposon Ty 1, Nature 313:243–246.
Mellor, J., Fulton, A. M., Dobson, M. J., Roberts, N. A., Wilson, W., Kingsman, A. J., and Kingsman, S. M., 1985b, The Ty transposon of Saccharomyces cerevisiae determines the synthesis of at least three proteins, Nucleic Acids Res. 13:6249–6263.
Mellor, J., Malim, M. H., Gull, K., Tuite, M. F., McCready, S., Dibbayawan, T., Kingsman, S. M., and Kingsman, A. J., 1985c, Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast, Nature 318:583–586.
Michel, M.-L., Mancini, M., Sobczack, E., Favier, V., Guetard, D., Bahraqui, E. M., and Tollias, P., 1988, Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles, Proc. Natl. Acad. Sci. USA 85:7957–7961.
Mills, K. H. G., Kitchin, P. A., Mahon, B. P., Barnard, A. L., Adams, S. E., Kingsman, S. M., and Kingsman, A. J., 1990, HIV p24-specific helper Tcell clones from immunized primates recognize highly conserved regions of HIV-1, J. Immunol. 144:1677–1683.
Moore, J. P., and Nara, P. L., 1991, The role of the V3 loop of gpl20 in HIV infection, AIDS 5(Suppl. 2):S21–S33.
Morein, J. P., Lovgren, K., Hogland, S., and Sundquist, B., 1987, The ISCOM: An immunostimulating complex, Immunol. Today 8:333–338.
Moss, B., 1991, Vaccinia virus: A tool for research and vaccine development, Science 252:1662–1667.
Nair, S., Zhou, F., Reddy, R., Huang, L., and Rouse, B. T., 1992, Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro, J. Exp. Med. 175:609–612.
Reddy, R., Zhou, F., Nair, S., Huang, L., and Rouse, B. T., 1992, In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes, J. Immunol. 148:1585–1589.
Rock, K. L., Rothstein, L., Fleischacker, C., and Gamble, S., 1992, Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen, J. Immunol. 148:3028–3033.
Rock, K. L., Rothstein, L., Gamble, S., and Fleischacker, C., 1993, Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules, J. Immunol. 150:438–446.
Roeder, S., and Fink, G., 1983, The yeast transposon, Ty, in: Mobile Genetic Elements (J. A. Shapiro, ed.), Academic Press, New York, pp. 299–328.
Schultz, M., Zinkernagel, R. M., and Hengartner, H., 1991, Peptide-induced antiviral protection by cytotoxic T cells, Proc. Natl. Acad. Sci. USA 88: 991–993.
Stover, C. K., de la Cruz, VF., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., Snapper, S. B., Barletta, R. G., Jacobs, J. R., Jr., and Bloom, B. R., 1991, New use of BCG for recombinant vaccines, Nature 351:456–460.
Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R. N., and Berzofsky, J. A., 1990, Induction of CD8+ cytotoxic T lymphocytes by immunization with purified HIV-1 envelope protein in ISCOMs, Nature 344:873–875.
Ulmer, J. B., Donnelly, J. J., Suezanne, E. P., Rhodes, G. H., Feigner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., Hawe, L. A., Leander, K. R., Martinez, D., Perry, H. C., Shiver, J. W., Montgomery, D. L., and Liu, M. A., 1993, Heterologous protection against influenza by injection of DNA encoding a viral protein, Science 259:1745–1749.
Weber, J. N., Clapham, P. R., Weiss, R. A., Parker, D., Roberts, C., Duncan, J., Weiler, I., Carne, C., Tedder, R. S., Pinching, A. J., and Cheingsong-Popov, R., 1987, Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralizing sera and association of anti-gag antibody with prognosis, Lancet 1:119–122.
Weldon, R. A., Erdie, C. R., Oliver, M. G., and Wills, J. W., 1990, Incorporation of chimeric Gag protein into retroviral particles, J. Virol. 64:4303–4310.
Williamson, V. M., 1983, Transposable elements in yeast, Int. Rev. Cytol. 83:1–25.
Wilson, W., Malim, M. H., Kingsman, A. J., and Kingsman, S. M., 1986, Expression strategies of the yeast retrotransposon Ty: A short sequence directs ribosomal frameshifting, Nucleic Acids Res. 14:7001–7015.
Wu, J.-Y., Gardner, B. H., Murphy, C. I., Seals, J. R., Kensil, C. R., Recchia, J., Beltz, G. A., Newman, G. W., and Newman, M. J., 1992, Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine, J. Immunol. 148:1519–1525.
Yu, X. F., Yuan, X., Matsuda, Z., Lee, T. H., and Essex, M., 1992, The matrix protein of HIV-1 is required for incorporation of viral envelope protein into mature virus, J. Virol. 66:4966–4971.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Adams, S.E., Kingsman, A.J. (1995). Retrovirus and Retrotransposon Particles as Antigen Presentation and Delivery Systems. In: Powell, M.F., Newman, M.J. (eds) Vaccine Design. Pharmaceutical Biotechnology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1823-5_34
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1823-5_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5737-7
Online ISBN: 978-1-4615-1823-5
eBook Packages: Springer Book Archive